The purpose of this proposal is to continue the Clinical Investigator Training Program (CITP) at the Fox Chase Cancer Center. The program is designed to support medical oncology, surgical oncology, radiation oncology and pathology fellows who have completed their clinical training are committed to developing careers in clinical oncology research. The overall goal of the program to provide highly focused individualized training to prepare investigators for careers in which advances in biotechnology, molecular biology and related disciplines can be integrated into well designed clinical trials. The program is organized along scientific program lines including: tumor biology, developmental therapeutics, immunobiology/immunotherapy, and radiobiology/radiotherapy to encourage interdisciplinary actions. Within these subgroups, mentors accomplished in clinical and translational research guide trainees through a two-year program with both clinical trial and laboratory components. This program which started with the support of a prior K12 award has been highly successful as six of eight graduated trainees have successfully established clinical research-based careers. This program will be overseen by both a coordinator leadership of the Medical Science Division. In addition to the individual research project, trainees will have continuous exposure to clinical trial design by becoming part of the process of protocol review by the Research Review Committee and Institutional Review Board, and as Assistant Director of the Protocol Office and Clinical Research Unit. An extensive, didactic exposure to clinical research methodology, with lectures relating to molecular biology, epidemiology, pharmacology and biostatistics is provided as well. The exact conference requirements will be tailored for each trainee in consultation with his/her mentor and with the approval of the advisory committee. Scheduled monitoring or each trainee's progress is provided by the mentor, area coordinator and advisory committee throughout the two-year period of training. At the conclusion of the two years, promising, productive trainees will have the opportunity for yearly competitive renewals for an additional year of funding to facilitate their transitions into independent investigators in clinical oncology research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA001728-08
Application #
2894316
Study Section
Special Emphasis Panel (ZCA1-GRB-J (01))
Program Officer
Lei, Ming
Project Start
1992-09-01
Project End
2002-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Cohen, Steven J; Alpaugh, R Katherine; Gross, Steve et al. (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6:125-32
Sundermeyer, Mark L; Meropol, Neal J; Rogatko, Andre et al. (2005) Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 5:108-13
Lewis, N L; Mullaney, M; Mangan, K F et al. (2004) Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients. Bone Marrow Transplant 33:71-8
Cohen, Steven J; Gallo, James; Lewis, Nancy L et al. (2004) Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol 53:513-8
Cohen, Steven J; Ho, Linus; Ranganathan, Sulabha et al. (2003) Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21:1301-6
Cheng, Jonathan D; Dunbrack Jr, Roland L; Valianou, Matthildi et al. (2002) Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 62:4767-72
von Mehren, M; Arlen, P; Gulley, J et al. (2001) The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 7:1181-91
von Mehren, M; Arlen, P; Tsang, K Y et al. (2000) Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 6:2219-28
Siegelmann-Danieli, N; Buetow, K H (1999) Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 79:456-63
Siegelmann-Danieli, N; Hanlon, A; Ridge, J A et al. (1998) Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients. J Clin Oncol 16:745-53

Showing the most recent 10 out of 14 publications